LA JOLLA, Calif., Feb. 27, 2014 /PRNewswire/ -- Regulus Therapeutics Inc . (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today provided an update on its corporate strategy and reported financial results for the fourth quarter and year ended December 31, 2013, including a summary of recent corporate highlights.
Help employers find you! Check out all the jobs and post your resume.
